4237919 said its normalized net income for the fiscal fourth quarter ended March 31 amounted to ¥23.74 per share, a decrease from ¥24.88 per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥1.93 billion, a decline of 5.1% from ¥2.04 billion in the prior-year period.

The normalized profit margin fell to 6.2% from 6.5% in the year-earlier period.

Total revenue decreased on an annual basis to ¥31.19 billion from ¥31.57 billion, and total operating expenses declined on an annual basis to ¥28.22 billion from ¥28.51 billion.

Reported net income decreased 13.7% from the prior-year period to ¥1.78 billion, or ¥21.81 per share, from ¥2.06 billion, or ¥25.13 per share.

For the year, the company's normalized net income totaled ¥144.49 per share, compared with ¥143.25 per share in the prior year.

Normalized net income was ¥11.78 billion, compared with ¥11.73 billion in the prior year.

Full-year total revenue totaled ¥128.34 billion, compared with ¥127.29 billion in the prior year, and total operating expenses grew on an annual basis to ¥110.43 billion from ¥109.17 billion.

The company said reported net income rose on an annual basis to ¥12.45 billion, or ¥152.72 per share, in the full year, from ¥12.31 billion, or ¥150.28 per share.

s of June 26, US$1 was equivalent to ¥123.96.Kobayashi Pharmaceutical Co. Ltd.

4237919 said its normalized net income for the fiscal fourth quarter ended March 31 amounted to ¥23.74 per share, a decrease from ¥24.88 per share in the year-earlier period.